Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
livescience - Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.
AI Summary: Early studies report that a widely used asthma medication can switch off a tumor immune‑evasion pathway and restore anti‑tumor immunity in models and early human data, improving responses in some hard‑to‑treat cancers including aggressive breast tumours. Researchers call for larger trials to confirm clinical benefit and safety.
- Asthma drug revives anti‑tumor immunity in resistant cancers (5)
- Mechanisms and meetings on immunotherapy resistance (5)
- All Other Stories
Asthma drug revives anti‑tumor immunity in resistant cancers
Mechanisms and meetings on immunotherapy resistance
All Other Stories
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks
James P. Allison wins AACR lifetime achievement award / 7 wks
Metabolic enzyme linked to immunotherapy benefit; routing metabolites may boost response / 1 month
Atezolizumab plus FOLFOX improves DFS in Stage III dMMR colon cancer / 1 month
AstraZeneca’s in‑vivo CAR‑T yields early responses but raises safety questions / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Health Disparities, Healthcare, Cancer Research, Product Recall and look for the RSS link.
StackHealth Time Machine